Search
Powered By HealthLine
Health Tools
 Mood Tracker
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Double-Dose Plavix Benefits Certain Patients, Study Finds

And higher-dose aspirin is no more effective than low dose, researchers say

By Steven Reinberg
HealthDay Reporter


Related Encyclopedia
 border=
Alzheimer's Disease
Aneurysms
Angina Pectoris
Angiogram
More...

Related Healthscout Videos
 border=
Drano for Clogged Arteries
Knee Replacement = Pain Replacement
Blood Lies
Disco CPR: Catch the Fever
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Angioplasty
Coronary Bypass Surgery
Erectile Dysfunction
More...

Related Drug Information
 border=
Accupril
Actonel
Altace
Avapro
More...

Related News Articles
 border=
Health Tip: Fears and Phobias
Health Tip: Reduce Your Risk of Atherosclerosis
A Deadly New Reason to Avoid Deer Ticks
Men May Have Better 'Cocktail Party' Hearing
More...

WEDNESDAY, Sept. 1 (HealthDay News) -- More isn't necessarily better when prescribing the two drugs commonly used to treat patients who are in danger of having a heart attack, Plavix (clopidogrel) and aspirin, a new study suggests.

Two reports on the data find that high doses of Plavix are good for some patients, but not all, while high-dose aspirin is no better than a low dose for preventing new heart attacks, other cardiac problems, stroke and death.

Text Continues Below



The findings suggest a need to assess the risks and benefits individually, experts say.

Patients who are at high risk for heart attack and stroke and low risk for bleeding are going to do well on a higher dose of Plavix, said Dr. Gregg Stone, author of an editorial in The Lancet.

"Patients who are at lower risk for atherosclerotic complications, but high risk for bleeding should be treated with a more conservative lower dose," added Stone, director of cardiovascular research and education at Columbia University Medical Center in New York City.

The reports are being released Wednesday to coincide with the meeting of the European Society of Cardiology in Stockholm. They are also published in the Sept. 1 online edition of The Lancet and in the Sept. 2 issue of the New England Journal of Medicine.

While aspirin and Plavix are mainstays of treatment for those at risk of having a heart attack, questions remain about proper dosing. Too little medicine won't prevent clotting, which can lead to heart attack, while too much can cause fatal bleeding.

To assess the best treatment regimens, the researchers assigned 25,086 patients at risk of having a heart attack (due to acute coronary syndrome) to a standard dose or double dose of Plavix and to high- or low-dose aspirin. Patients on the standard dose of Plavix got 300 milligrams (mg) the first day followed by 75 mg daily, while those with the double dose took 600 mg on day one, followed by 150 mg for six days and 75 mg thereafter. Patient outcome was evaluated after 30 days.

Page:  1 | 2 | 3 | Next >>

Copyright © 2010 HealthDay. All rights reserved.
Last updated 9/1/2010

Related Links
 border=
From Healthscout's partner site on heart disease, MyHeartCentral.com
Learn about heart disease symptoms.
Get more information on heart disease treatment for your health!
What can you do to prevent heart disease? Prevention details here.




SOURCES: Shamir Mehta, M.D., associate professor of cardiology, McMaster University, Hamilton, Ontario, Canada; Gregg Stone, M.D., director, cardiovascular research and education, Columbia University Medical Center, New York City; Gregg C. Fonarow, M.D., professor, cardiology, University of California, Los Angeles; Sept. 2, 2010, New England Journal of Medicine; Sept. 1, 2010, The Lancet, online


HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2011. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire